GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viva Biotech Holdings (HKSE:01873) » Definitions » Beneish M-Score

Viva Biotech Holdings (HKSE:01873) Beneish M-Score : -2.69 (As of Jun. 06, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Viva Biotech Holdings Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.69 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Viva Biotech Holdings's Beneish M-Score or its related term are showing as below:

HKSE:01873' s Beneish M-Score Range Over the Past 10 Years
Min: -3.24   Med: -1.93   Max: -0.64
Current: -2.69

During the past 8 years, the highest Beneish M-Score of Viva Biotech Holdings was -0.64. The lowest was -3.24. And the median was -1.93.


Viva Biotech Holdings Beneish M-Score Historical Data

The historical data trend for Viva Biotech Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viva Biotech Holdings Beneish M-Score Chart

Viva Biotech Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial -1.70 -2.15 -0.64 -3.24 -2.69

Viva Biotech Holdings Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.64 - -3.24 - -2.69

Competitive Comparison of Viva Biotech Holdings's Beneish M-Score

For the Biotechnology subindustry, Viva Biotech Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viva Biotech Holdings's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Viva Biotech Holdings's Beneish M-Score falls into.



Viva Biotech Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Viva Biotech Holdings for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1835+0.528 * 1.0006+0.404 * 0.9945+0.892 * 0.8872+0.115 * 0.7646
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1181+4.679 * -0.06705-0.327 * 0.7381
=-2.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was HK$549 Mil.
Revenue was HK$2,358 Mil.
Gross Profit was HK$808 Mil.
Total Current Assets was HK$2,221 Mil.
Total Assets was HK$8,149 Mil.
Property, Plant and Equipment(Net PPE) was HK$1,817 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$231 Mil.
Selling, General, & Admin. Expense(SGA) was HK$448 Mil.
Total Current Liabilities was HK$1,678 Mil.
Long-Term Debt & Capital Lease Obligation was HK$1,040 Mil.
Net Income was HK$-127 Mil.
Gross Profit was HK$0 Mil.
Cash Flow from Operations was HK$419 Mil.
Total Receivables was HK$522 Mil.
Revenue was HK$2,657 Mil.
Gross Profit was HK$911 Mil.
Total Current Assets was HK$2,165 Mil.
Total Assets was HK$8,845 Mil.
Property, Plant and Equipment(Net PPE) was HK$2,194 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$207 Mil.
Selling, General, & Admin. Expense(SGA) was HK$452 Mil.
Total Current Liabilities was HK$2,984 Mil.
Long-Term Debt & Capital Lease Obligation was HK$1,013 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(548.646 / 2357.726) / (522.476 / 2657.369)
=0.232701 / 0.196614
=1.1835

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(910.881 / 2657.369) / (807.681 / 2357.726)
=0.342776 / 0.342568
=1.0006

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2221.375 + 1816.699) / 8148.556) / (1 - (2165.094 + 2193.693) / 8845.335)
=0.504443 / 0.507222
=0.9945

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2357.726 / 2657.369
=0.8872

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(207.099 / (207.099 + 2193.693)) / (231.024 / (231.024 + 1816.699))
=0.086263 / 0.11282
=0.7646

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(448.073 / 2357.726) / (451.659 / 2657.369)
=0.190045 / 0.169965
=1.1181

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1039.939 + 1678.052) / 8148.556) / ((1012.592 + 2984.484) / 8845.335)
=0.333555 / 0.451885
=0.7381

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-127.002 - 0 - 419.36) / 8148.556
=-0.06705

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Viva Biotech Holdings has a M-score of -2.69 suggests that the company is unlikely to be a manipulator.


Viva Biotech Holdings Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Viva Biotech Holdings's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Viva Biotech Holdings (HKSE:01873) Business Description

Traded in Other Exchanges
Address
735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318
Viva Biotech Holdings is an integrated drug discovery platform. The company's operating segment includes Drug discovery services and Contract Development Manufacture Organisation (CDMO) and commercialisation services. It generates maximum revenue from the Contract Development Manufacture Organisation (CDMO) and commercialisation services segment. The Contract Development Manufacture Organisation ("CDMO") and commercialisation services segment includes contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations.
Executives
Mao Chen Cheney 2101 Beneficial owner
Wu John Jiong 2201 Interest of corporation controlled by you
Fenghe Harvest Ltd 2101 Beneficial owner
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Mao Jun 2501 Other
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
Zhou Min 2202 Interest of your spouse
Intertrust (singapore) Ltd. 2301 Trustee
Z&m International Holdings Limited 2201 Interest of corporation controlled by you
Zhang And Sons Limited 2101 Beneficial owner

Viva Biotech Holdings (HKSE:01873) Headlines

No Headlines